Dianthus Therapeutics’ claseprubart has met its primary and secondary endpoints during a Phase II trial in generalised myasthenia gravis (gMG). During the MaGic study (NCT06282159), the active ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback